Zoster Treatment Market Analysis

Route of Administration Segment Analysis

Oral subsegment leads the segment and is expected to hold the zoster treatment market share of 49.2% by 2037. Oral delivery leads the way because of high compliance from patients, global availability, and convenience of dosing. According to the U.S. FDA, the majority of approved first-line zoster drugs are oral antivirals. Their widespread application in both outpatients and inpatients is among the leading revenue contributors. In addition, data by the Agency for Healthcare Research and Quality reveals that oral outpatient prescription occupies more than 60.5% of antiviral use among patients aged over 50 years, which is proof of high drug adherence and cost-saving.

Drug Class Segment Analysis

Antivirals dominate the segment and are expected to hold the market share of 42.7% by 2037. Acyclovir, Valacyclovir, and Famciclovir are some of the antivirals that remain a standard treatment for herpes zoster disease, as they can minimize the replication of the virus and reduce the risk of postherpetic neuralgia. As per the National Institute of Neurological Disorders and Stroke, early administration of antivirals minimizes the pain and complications in the long term. Additionally, the report from the CDC has stated that the U.S. usage of antivirals in immunocompromised and immunocompetent adults is the key to the clinical management approach.

Our in-depth analysis of the global zoster treatment market includes the following segments: